Reframing ME/CFS: toward a unified mechanistic model of chronic post-infectious diseases.

Publication date: May 22, 2026

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multisystem illness marked by post-exertional malaise (PEM), cognitive dysfunction, autonomic disturbance, and impaired physiological resilience. Historically, the absence of validated biomarkers, heterogeneous definitions, and limited investigative capacity have complicated mechanistic interpretation and contributed to the use of psychosocial and rehabilitative frameworks in clinical practice and in parts of the literature. Advances in systems biology, accelerated by Long-COVID research, have transformed our understanding of post-infectious syndromes, implicating persistent immune dysregulation, mitochondrial and metabolic reprogramming, endothelial and microvascular dysfunction, abnormal coagulation, lipid-mediated signalling, extracellular vesicle communication, and viral protein-associated immune activation. This review charts the shift from early post-infectious observations through psychosocial dominance to contemporary biological frameworks, emphasising that pathology is state-dependent and revealed under physiological stress. ME/CFS is thus reframed here as a disorder of impaired adaptive capacity within post-infectious disease biology.

Open Access PDF

Concepts Keywords
Encephalomyelitis Immune dysregulation
Mitochondrial Impaired physiological resilience
Pathology Post-Exertional Malaise (PEM)
Rehabilitative Post-infectious disease biology
Viral

Semantics

Type Source Name
disease MESH infectious diseases
disease MESH Myalgic encephalomyelitis
disease MESH cognitive dysfunction
disease MESH syndromes
pathway REACTOME Infectious disease
pathway REACTOME Reproduction
disease MESH included
disease MESH Long COVID
disease MESH pain
disease MESH COVID 19
disease MESH NHS
disease MESH mitochondrial dysfunction
disease MESH CBT
disease MESH symptom exacerbation
drug DRUGBANK Fibrinogen Human
disease MESH infection
drug DRUGBANK Coenzyme M
pathway REACTOME Metabolism
disease MESH chronic diseases
pathway REACTOME Translation
drug DRUGBANK Oxygen
drug DRUGBANK Isoxaflutole
drug DRUGBANK ATP
drug DRUGBANK Calcium
pathway REACTOME Apoptosis
disease MESH injury
pathway KEGG Oxidative phosphorylation
pathway KEGG Viral replication
disease MESH inflammation
pathway KEGG Platelet activation
drug DRUGBANK Nitric Oxide
pathway REACTOME Autophagy
pathway REACTOME Mitophagy
drug DRUGBANK Cholesterol
disease MESH haemolysis
disease MESH relapse
pathway REACTOME Release
disease MESH viral infection
disease MESH post infectious disorders
disease MESH hyperthermia
drug DRUGBANK Etoperidone
disease MESH encephalomyelitis
disease MESH fatigue
disease MESH encephalopathy
disease MESH pneumonitis
disease MESH encephalitis
pathway REACTOME Immune System
disease MESH Death
disease MESH Dis
drug DRUGBANK Thrombin
disease MESH coinfections
disease MESH neurological disorders
drug DRUGBANK Guanosine
drug DRUGBANK Carboxyamidotriazole
disease MESH thromboinflammation
disease MESH Bos
drug DRUGBANK Pumactant
disease MESH Glass
pathway KEGG Purine metabolism
disease MESH paralyses
disease MESH cardiovascular disease
disease MESH Traps
disease MESH allergy
disease MESH rheumatic diseases
disease MESH Systemic Sclerosis
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH Arthritis
drug DRUGBANK Tolbutamide
disease MESH Cancer
disease MESH coronavirus infection
drug DRUGBANK L-Arginine
disease MESH autoimmune disease
drug DRUGBANK Naltrexone
disease MESH Cachexia
disease MESH Sarcopenia
disease MESH Neuroinflammation
drug DRUGBANK Water

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *